The Technical Analyst
Strongbridge Biopharma [SBBP]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Strongbridge Biopharma Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.52% $2.00
America/New_York / 31 des 1970 @ 19:00
| RATING 2021-10-05 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/20 | 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.889 - 2.11 ( +/- 5.55%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-10-05 | Cdk Associates, L.l.c. | Sell | 8 060 682 | Ordinary Shares, $0.01 par value |
| 2021-10-05 | Cdk Associates, L.l.c. | Sell | 2 220 000 | Ordinary Shares Warrant (right to buy) |
| 2021-10-05 | Wilhoit Scott L. | Sell | 109 510 | Ordinary Shares |
| 2021-10-05 | Wilhoit Scott L. | Sell | 649 000 | Stock Option (Right to Buy) |
| 2021-10-05 | Kollender Richard S | Sell | 234 229 | Ordinary Shares |
| INSIDER POWER |
|---|
| 0.00 |
| Last 99 transactions |
| Buy: 6 188 774 | Sell: 17 044 650 |
Forecast:
01:40 - $2.01
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.00 (1.52% ) |
| Volume | 0.685 mill |
| Avg. Vol. | 0.316 mill |
| % of Avg. Vol | 216.43 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SBBP
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SBBP
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company offers Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trials that for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.
Latest Press Releases
2021-10-05 16:05:00 - Press Release
Xeris Pharmaceuticals Completes Acquisition Of Strongbridge Biopharma
Chicago--(business wire)--xeris pharmaceuticals, inc. (“xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of strongbridge biopharma plc (nasdaq: sbbp) (“strongbridge”). under the terms of the acquisition agreement, the businesses of xeris and strongbridge are now combined under xeris biopharma holdin
2021-10-05 16:01:00 - Press Release
Strongbridge Biopharma Plc Announces Completion Of Acquisition By Xeris Pharmaceuticals, Inc.
Dublin, ireland and trevose, pa., oct. 05, 2021 (globe newswire) -- strongbridge biopharma plc (nasdaq: sbbp) (the “company” or “strongbridge”) today announced that the high court of ireland (the "court") has approved the previously announced proposed acquisition of strongbridge by xeris pharmaceuticals, inc. (nasdaq: xers) (“xeris”) by means of a scheme of arrangement (the "scheme") under chapter 1 of part 9 of the irish companies act 2014 (the "act").
2021-09-23 16:01:00 - Press Release
Strongbridge Biopharma Plc Announces Court Hearing Date To Approve Proposed Acquisition By Xeris Pharmaceuticals, Inc.
Dublin, ireland and trevose, pa., sept. 23, 2021 (globe newswire) -- strongbridge biopharma plc (nasdaq: sbbp) (the “company” or “strongbridge”) today announced that the high court of ireland (the “court”) has set the date of the final court hearing to sanction the proposed acquisition of strongbridge by xeris pharmaceuticals, inc. (“xeris”) by means of scheme of arrangement (the “scheme”) under chapter 1 of part 9 of the irish companies act 2014 (the “act”).
2021-09-08 16:01:00 - Press Release
Strongbridge Biopharma Plc Announces Shareholder Approval Of Proposed Acquisition By Xeris Pharmaceuticals, Inc.
Dublin, ireland and trevose, pa., sept. 08, 2021 (globe newswire) -- strongbridge biopharma plc (nasdaq: sbbp) (the “company” or “strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of strongbridge by xeris pharmaceuticals, inc. (nasdaq: xers) (“xeris”). as described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “court meeting”) and at an extraordinary general meeting of shareholders (the “egm”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the strongbridge shareholder meetings held on september 8, 2021 in pennsylvania, united states of america...
2021-08-31 07:30:00 - Press Release
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma Plc Shareholders Vote “for” The Transaction With Xeris
Glass lewis joins iss in recommending strongbridge shareholders vote “for” transaction with xeris
Latest News
2021-10-05 16:05:00 - Business Wire
Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (“Xeris”), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (Nasdaq: SBBP) (“Strongbridge”). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdin
2021-10-05 16:01:00 - GlobeNewsWire
Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) (“Xeris”) by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act").
2021-09-23 16:01:00 - GlobeNewsWire
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the “Court”) has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (“Xeris”) by means of scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Act”).
2021-09-08 16:01:00 - GlobeNewsWire
Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) (“Xeris”). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the “Court Meeting”) and at an extraordinary general meeting of shareholders (the “EGM”) were in favor of the transaction, representing (in each case) approximately 67 percent of the shares outstanding and eligible to be voted at each of the Strongbridge shareholder meetings held on September 8, 2021 in Pennsylvania, United States of America...
2021-08-31 07:30:00 - GlobeNewsWire
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris
2021-08-30 07:30:00 - GlobeNewsWire
Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals
2021-08-05 10:39:51 - Zacks Investment Research
Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
Strongbridge Biopharma (SBBP) delivered earnings and revenue surprises of 20.00% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
2021-08-05 07:30:00 - GlobeNewsWire
Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
~ Reports KEVEYIS ® (dichlorphenamide) Second Quarter 2021 Revenue of $10.0 Million, a 28 Percent Increase Compared to $7.8 Million of Revenue During Second Quarter of 2020 ~
2021-08-02 07:30:00 - GlobeNewsWire
Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders.
2021-07-29 08:15:00 - GlobeNewsWire
Strongbridge Biopharma plc Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
DUBLIN, Ireland and TREVOSE, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced in accordance with Rule 2.10 of the Irish Takeover Rules that, as of the close of business on July 28, 2021, Strongbridge's issued share capital, excluding treasury shares, is comprised of 67,828,952 ordinary shares with a par value of $0.01 per share. Strongbridge's ordinary shares are traded on the Nasdaq under the symbol SBBP. The International Securities Identification Number (ISIN) of the Strongbridge ordinary shares is IE00BYZ5XL97.